Showing 2331-2340 of 4063 results for "".
- Lilly, Incyte’s Olumiant Shows “Significant Effect” on COVID-19 Recovery Timeshttps://modernod.com/news/lilly-incytes-olumiant-shows-significant-effect-on-covid-19-recovery-times/2478401/Eli Lilly and Incyte shared more details, including mortality data, from the ongoing ACTT 2 trial evaluating their JAK1/JAK2 inhibitor Olumiant (baricitinib) in combination with Gilead Sciences’ Veklury (remdesivir) in patients with COVID-19 infection. The companies said last month that the
- In Memoriam: Alan S. Crandall, MDhttps://modernod.com/news/renowned-ophthalmologist-and-humanitarian-alan-s-crandall-md-dies-at-age-73/2478360/Alan S. Crandall, MD, arguably known most for his humanitarian efforts spanning a career of nearly 40 years, died October 2 following a sudden illness. Dr. Crandall practiced at the John A. Moran Eye Center at University of Utah Health for 39 years. Most recently, he served as presidential profes
- Early Data Show Regeneron’s Antibody Cocktail Cuts Viral Load, Eases COVID-19 Symptomshttps://modernod.com/news/early-data-show-regenerons-antibody-cocktail-cuts-viral-load-eases-covid-19-symptoms/2478347/Regeneron Pharmaceuticals said Tuesday that adding REGN-COV2 to standard-of-care reduced viral load as well as the time to symptom alleviation in non-hospitalized patients with COVID-19. The company noted that first data from an ongoing adaptive phase 1/2/3 trial of its investigational dual antib
- Inovio’s COVID-19 Vaccine Candidate INO-4800 Hit by FDA Partial Holdhttps://modernod.com/news/inovios-covid-19-vaccine-candidate-ino-4800-hit-by-fda-partial-hold/2478341/Inovio Pharmaceuticals said that the FDA placed a partial clinical hold on a planned phase 2/3 study of its COVID-19 vaccine candidate INO-4800. According to Inovio, the FDA has “additional questions” about the planned trial, including the CELLECTRA 2000 delivery device to be
- Lilly, Incyte’s Olumiant Cuts Recovery Time When Added to Veklury in Hospitalized COVID-19 Patientshttps://modernod.com/news/lilly-incytes-olumiant-cuts-recovery-time-when-added-to-veklury-in-hospitalized-covid-19-patients/2478281/Eli Lilly and Incyte reported Monday that the JAK1/JAK2 inhibitor Olumiant (baricitinib) in combination with Gilead Sciences’ Veklury (remdesivir) met the primary endpoint of the ACTT 2 study by significantly reducing the time to recovery compared to Veklury alone in hospitalized patients w
- Ocular Therapeutix Announces Resolution of FDA Warning Letter Related to ReSure Sealanthttps://modernod.com/news/ocular-therapeutix-announces-resolution-of-fda-warning-letter-related-to-resure-sealant/2478250/Ocular Therapeutix announced it has received a letter from the FDA, dated September 2, 2020, closing out the Warning Letter it received from the FDA on October 18, 2018 concerning ReSure Sealant. The violation cited in Warning Letter (CMS #564663) has been addressed and Ocular is committed to sus
- LumiThera Receives $1.5 Million Grant From National Eye Institute to Support Trial for Treating Diabetic Retinopathy and Macular Edemahttps://modernod.com/news/lumithera-receives-1-5-million-grant-from-national-eye-institute-to-support-trial-for-treating-diabetic-retinopathy-and-macular-edema/2478242/LumiThera announced it is a recipient of a small business innovative research (SBIR) phase 2 grant from the National Institute of Health (NIH) and the division of the National Eye Institute (NEI). The grant supports a prospective, randomized, multicenter human clinical trial in U.S. subjects diag
- Mylan and Biocon Biologics Announce Launch of Semglee in the US for Patients With Diabeteshttps://modernod.com/news/mylan-and-biocon-biologics-announce-launch-of-semglee-in-the-us-for-patients-with-diabetes/2478220/Mylan and Biocon Biologics India announced the US launch of Semglee (insulin glargine injection) in vial and pre-filled pens, approved to help control high blood sugar in adult and pediatric patients with type 1 diabetes and adults with type 2 diabetes. It is not recommended for the treatment of
- EU Wraps Up Advanced Talks With Moderna for COVID-19 Vaccine Supply Dealhttps://modernod.com/news/eu-wraps-up-advanced-talks-with-moderna-for-covid-19-vaccine-supply-deal/2478195/The European Commission said Monday that it concluded exploratory talks with Moderna for an initial purchase of 80 million doses of the company’s mRNA vaccine candidate against SARS-CoV-2. The contractual framework would also provide an option for EU member states to purchase an additional
- Trefoil Therapeutics Begins First Clinical Trial of Regenerative Treatment for Patients with Corneal Endothelial Dystrophieshttps://modernod.com/news/trefoil-therapeutics-begins-first-clinical-trial-of-regenerative-treatment-for-patients-with-corneal-endothelial-dystrophies/2478175/Trefoil Therapeutics announced it has initiated the first clinical trial of its engineered Fibroblast Growth Factor-1 TTHX1114 for the regenerative treatment of people with corneal endothelial dystrophies (CED), including Fuchs Endothelial Corneal Dystrophy. The phase 1/2 trial (INTREPID)